

Viral hepatitis in persons living with HIV in the post-COVID era

Vicente Soriano^{1*}, Víctor Moreno-Torres^{1,2}, Carmen de Mendoza², Octavio Corral¹, and Pablo Barreiro^{1,3}

¹UNIR Health Sciences School, Madrid; ²Puerta de Hierro University Hospital, Madrid; ³Isabel Zendal Emergency Hospital, Madrid, Spain

Abstract

Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes in poor income regions and in non-vaccinated travelers. In high-income countries, outbreaks of hepatitis A occur in men having sex with men (MSM) and chronic hepatitis E is occasionally reported among PLWH with severe immunodeficiency. Chronic hepatitis B, C, and D are frequent in PLWH in highly endemic regions and globally in persons who inject drugs (PWID) and MSM. Progression to liver cirrhosis and development of hepatocellular carcinoma (HCC) is major clinical complications in coinfecting patients. Current estimates for PLWH are of 38 million worldwide. Roughly 12% have chronic viral hepatitis (5 million). Coinfection figures are of 5-10% for HBV (2-4 million), 4% for HCV (1.5 million), and 15% of HBsAg+ for HDV (0.5 million). Oral direct-acting antivirals (DAA) cure almost all treated patients with hepatitis C. However, given that there is no protective HCV immunity, PLWH with high-risk behaviors may experience HCV reinfection episodes. Tenofovir is the drug of choice in PLWH with chronic hepatitis B, given its dual effect on HIV and HBV. Lifelong oral tenofovir suppresses HBV replication and ameliorate liver damage. However, the risk of HCC persists even in the absence of cirrhosis. Finally, HDV causes the worst of viral hepatitis with faster progression to cirrhosis and HCC. An entry inhibitor, bulevirtide, has recently been approved and another drug, Isonafarnib, is completing Phase 3 trials. Combination antiviral therapy for hepatitis D could improve dramatically the poor prognosis of HIV-HDV coinfecting patients. The resumption of good medical practices in PLWH after the big disruption caused by COVID-19 will reduce the burden of viral hepatitis coinfections. Renewed efforts on HAV and HBV vaccination of susceptible individuals and earlier and wider prescription of antiviral therapy for HBV, HCV, and/or HDV coinfection should be prioritized in PLWH. The benefits of innovative strategies for viral hepatitis, including pre-exposure prophylaxis or use of long-acting antivirals, warrant further consideration in PLWH.

Keywords

HIV. Hepatitis B. Hepatitis C. Hepatitis delta. Coinfection. Antiviral therapy.

*Correspondence to:

Vicente Soriano
E-mail: vicente.soriano@unir.net

Received in original form: 22-02-2023
Accepted in final form: 01-03-2023
DOI: 10.24875/AIDSRev.M23000061

Introduction

Coinfection with hepatitis viruses is frequent in persons living with HIV (PLWH). This is largely explained by the sharing of transmission routes. Outbreaks of acute viral hepatitis among youth engaged in high-risk behaviors, especially among persons who injected drugs (PWID) and men having sex with men (MSM) were frequent in the 80s and 90s¹. Following the widespread use of HBV vaccines, acute episodes of hepatitis B and delta declined. Since the 2000s, however, outbreaks of acute hepatitis A² and acute hepatitis C³ have been reported in PLWH, especially among MSM.

The biggest clinical burden of viral hepatitis in PLWH is attributed to chronic hepatitis B, C, and delta. Progression to liver cirrhosis and development of hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in coinfecting patients⁴⁻⁶.

Current estimates from UNAIDS for PLWH are of 38 million worldwide, of whom 25 million live in Sub-Saharan Africa⁷. Roughly 1.5 million new HIV infections occur each year. Despite the increased uptake of antiretroviral treatment, approximately 15% of HIV individuals are not treated. This is mostly due to difficulties in access to medical care (especially in poor income countries) or because infected individuals are not aware of their status (persons neither tested nor diagnosed). This subset of untreated but infected subjects does not benefit from antiretrovirals individually (and, therefore, may progress to AIDS) and it is the major source for HIV transmission to others. Given that PLWH that are treated and have undetectable viral load are no longer infectious⁸, an effect known as undetectable=untransmittable (U=U)⁷, antiretroviral therapy is nowadays recommended to everyone HIV-positive and given as early as possible upon diagnosis⁹.

The current HIV-1 pandemic can be split into three major forms. The first mostly affects Sub-Saharan Africa and is the largest, with estimates of 25 million PLWH. Heterosexual transmission is the predominant mechanism of contagion. Women are slightly more affected than men (roughly 55%). Although mother-to-child transmission has drastically declined, HIV infections in children and adolescents continue to occur in poor regions. The second HIV pandemic form mostly affects North America and Europe, but also Japan and Australia, with estimates of 3 million PLWH. MSM and PWID are by far the most affected high-risk populations. The third HIV pandemic form mostly occurs in

Latin America and Asia. It evolves heterogeneously between the two prior forms, affecting sexually active individuals with a variable and larger weight of MSM and PWID (Fig. 1).

Since the mid 90s, immunodeficiency directly caused by HIV has become rare among PLWH thanks to the advent of triple combination antiretroviral therapies^{8,9}. As indirect result, coinfection with viral hepatitis soon emerged as an important cause of clinical complications and shorter survival in PLWH⁴⁻⁶. Given shared transmission routes, nowadays chronic viral hepatitis continues to be among the most frequent causes of morbidity and mortality in PLWH^{10,11}. This is particularly true in Sub-Saharan Africa, where high prevalence rates occur along with low access to antiviral therapies¹². In Western countries, the advent of effective antiviral therapies for HBV and HCV and high HBV vaccine coverage have reduced the clinical burden of hepatitis coinfections in PLWH¹¹. However, migration flows from highly endemic regions, HBV vaccine waning and HCV reinfections keep viral hepatitis as a major issue in PLWH. Figure 2 records graphically the global epidemiological burden and intersection of HIV and viral hepatitis.

In this review, we will update current knowledge and epidemiological information for each of the hepatitis viruses in PLWH. We will end discussing new strategies aimed to reduce the burden of HIV-hepatitis coinfections in the new post-COVID era, acknowledging the global negative impact of the coronavirus pandemic on both HIV and hepatitis care.

Hepatitis A

The hepatitis A virus (HAV) is a small single stranded RNA non-enveloped virus. It is mostly transmitted by the fecal-oral route. Poor hygiene, contaminated water and food, and oral-anal sex favor HAV contagion. There are three human genotypes (I-III). Dogs are the closest animal reservoir. Table 1 summarizes the main differential features of hepatitis viruses.

Natural HAV immunity is lifelong. A protective effective vaccine was marketed two decades ago. Although one shot provides short-term protection, two shots are recommended to attain long-lasting immunity, what is particularly true for patients with immune dysfunction, including PLWH¹³⁻¹⁶. Hepatitis A generally cause mild symptoms in children but in adults may produce fever, asthenia, nausea, and jaundice. It never evolves to chronicity. Despite presenting as an acute self-limited illness, HAV particles may be eliminated by feces for




Figure 1. Major epidemiological forms of the HIV-1 pandemic.
MSM: men having sex with men; PWID: persons who inject drugs.




Figure 2. Intersection between HIV and viral hepatitis globally.
PLWH: persons living with HIV.

long periods after clinical recovery, especially in immunosuppressed individuals¹⁷.

Most countries in Africa, Asia, and Latin America show high endemicity for HAV. Travelers from North America, the European Union, Japan, Australia, New Zealand, and a few other high-income countries are recommended to be vaccinated before going overseas.

Local outbreaks of hepatitis A in adults have been reported in high income countries among MSM, linked to anal sex¹⁸⁻²¹. These surges are a reminder of inadequate vaccination for this preventable viral disease. In a cohort of more than 3000 PLWH in Texas, < 10% of patients susceptible to HAV had been vaccinated after 2 years in care. MSM and those with HBV or HCV

Table 1. Main differential features of viral hepatitis

	HAV	HBV	HCV	HDV	HEV
Genome (nt)	RNA (7.5 Kb)	DNA (3.2 Kb)	RNA (9.6 Kb)	RNA (1.7 Kb)	RNA (7.2)
Genotypes	3 (I-III)	10 (A-J)	6 (1-6)	8 (1-8)	4 (1-4)
Major transmission	Orofecal	Sexual, Parenteral, vertical	Parenteral, sexual	Sexual, Parenteral	Orofecal
Risk populations	Poor hygiene, MSM	MSM, PWID, MSP	PWID, MSP	PWID, MSM, MSP	Poor hygiene Not cooked meat
Chronicity	No	Yes (> 90% in newborns; < 5% in adults)	Yes (75%)	Yes (more in superinfection than in coinfection)	Rare (immunosuppressed)
Clinical features	Jaundice more frequent in adults	High risk of liver cancer with age	Reinfections after cure following new exposures	Faster progression to cirrhosis	25% risk of stillbirth and/or death in pregnant women
Antivirals	No	Yes	Yes	Yes	No
Vaccines	Yes	Yes	No	No	Yes (China)

PWID: persons who inject drugs; MSM: men who have sex with men; MSP: multiple sex partners, HAV: hepatitis A virus, HBV: hepatitis B virus, HCV: hepatitis C virus, HDV: hepatitis D virus, HEV: hepatitis E virus

infection were more likely receive HAV vaccination¹¹. A Spanish cohort of 272 HAV-susceptible PLWH also reported low HAV vaccine uptake, with only 38% undergoing vaccination over a 10-year period. Nearly 10% of those vaccinated did not show HAV seroconversion, and one individual lost HAV antibodies. Several HAV outbreaks occurred during follow-up, 60% in non-immunized MSM¹¹.

To examine optimal strategies for HAV re-vaccination in those with ineffective initial vaccination, a Taiwanese study randomly assigned 102 PLWH to 1 or 2 HAV vaccine shots after initial non-response or seroreversion. There was no significant difference in seroconversion with 1 dose (79%) versus 2 doses (84%). Those with prior seroreversion responded to either 1 or 2 doses, but the latest led to a 2-fold higher HAV antibody level at week 24¹¹.

Hepatitis B

The hepatitis B virus (HBV) is a small partially double stranded DNA enveloped virus that uses the NTCP receptor to enter hepatocytes. There are ten HBV gen-

otypes (named A to J), each with a characteristic geographic distribution and differential pathogenicity²².

The most recent estimate of the number of individuals with chronic hepatitis B is 316 million, which represents 4.5% of the 8 billion World population²³. Countries with the largest number of chronic hepatitis B patients are China, India, Nigeria, Indonesia, and the Philippines (Fig. 3).

The prevalence of chronic HBV infection has steadily declined since 1990, particularly in children, following the introduction of universal infant hepatitis B vaccination²². The additional contribution of antiviral therapy suppressing viremic and therefore, infectious- carriers are lower and mostly restricted to high-income countries.

In 2016, only 10% of people with chronic HBV infection were diagnosed, and only 5% of those eligible for therapy were receiving antiviral treatment^{24,25}. By 2021, the WHO estimated that 30 million people with chronic HBV infection were diagnosed but < 7 million were treated. Hepatitis B produces more than 600,000 deaths annually. Moreover, estimates for liver cancer due to HBV are 40% globally but up to 65% for China²³.




Figure 3. Hepatitis B. Global geographic distribution and major endemic regions.

Attaining HBV virologic suppression can take a long time, particularly in HIV/HBV-coinfected individuals. Of 222 starting tenofovir-based treatment in the Swiss HIV cohort, 84% had detectable HBV-DNA and 58% had levels above 2000 IU/mL. HBV viremia persisted in 27% at 2 years and in 18% at their latest follow-up. Persistent viremia was associated with high baseline HBV-DNA level and advanced HIV disease¹¹.

In the Swiss HIV cohort, of 272 HIV/HBV-coinfected patients, HBsAg loss occurred in 8% during the first 2 years of tenofovir therapy and in 16% after a median of 8.4 years of follow-up, which is higher than generally seen in HBV mono-infection. When HBsAg clearance occurred, more than half (54%) developed anti-HBs antibodies, suggesting durable immunologic control¹¹.

Hepatitis C

The hepatitis C virus (HCV) is a small enveloped particle with one single stranded RNA genome. All the replication cycle of HCV occurs in the cytosol of infected hepatocytes. In contrast with the intranuclear HBV episomal form or the HIV provirus, there is no persistent HCV genomic cell reservoir²⁶. This finding explains that therapeutic HCV eradication is feasible with potent antivirals whereas blocking of HBV or HIV replication requires lifelong antivirals.

Following parenteral or sexual exposure, HCV generally causes asymptomatic or mild symptomatic acute hepatitis C. Roughly two-thirds may progress to chronicity²⁷. However, individuals with immunosuppression, including PLWH, show an increased risk of chronic hepatitis C along with a faster progression of liver disease³⁻⁵.

There are six major HCV genotypes, each with a characteristic geographic distribution, pathogenicity, and susceptibility to antiviral agents²⁷. HCV genotypes 1, 2, and 3 are widely distributed worldwide and produce most infections in North America, the European Union, and Japan. HCV genotype 4 predominates in North Africa and the Middle East. HCV genotype 5 circulates in South Africa and HCV genotype 6 in South-east Asia.

The five countries with the current largest number of chronic viremic hepatitis C patients are China, Pakistan, India, Bangladesh, and Russia (Fig. 4). Egypt is no longer in this list after undergoing a massive treatment campaign a couple of years ago, supported by international agencies and pharma companies²⁸.

From a total of 115 million people with HCV antibodies by 2015, odds were six times higher in PLWH (6.2% rate). The estimated number of PLWH with active HCV infection was 2.3 million before direct acting antivirals (DAA) became widely available²⁹, of which 1.4 million were in PWID. With the uncertainty of how many PLWH




Figure 4. Hepatitis C. Global geographic distribution and major endemic regions.

with hepatitis C have been treated with DAA since then, we estimate that considering high diagnosis rates in PLWH, frequent HCV reinfections, and challenges in medication access, among others, roughly one-third of HIV-HCV coinfecting patients have cured hepatitis C by 2023, acknowledging that the highest cure rates should have occurred in resource rich countries. Thus, HIV-HCV coinfection should still affect roughly 1.5 million people, which represents 4% of PLWH worldwide.

In 2013, HCV treatment was transformed by the introduction of oral DAA therapies that cure $\geq 95\%$ of patients. Broad DAA access has a treatment-as-prevention (TasP) effect on primary HCV incidence among PLWH³⁰. Response rates in PLWH are as good as in HCV-monoinfected individuals³¹. Hence, HCV in PLWH behaves as a microelimination population on track to meet the WHO's 80% HCV incidence reduction target by 2030²⁵. However, it should be noted that HCV reinfections hamper this benefit in certain populations, such as PWID sharing needles and MSM with multiple sexual partners^{30,32}.

In an examination of the European HCV care cascade in PLWH, the EuroSIDA cohort reported 90% ever tested for HCV antibodies, with 24% with active infection by HCV-RNA, with highest prevalence (45%) in Central-Eastern Europe. Overall, 65% of those diagnosed had ever been treated and nearly half had been cured¹¹. Spain has made some of the most substantial progress toward HCV elimination. In a nationwide

seroprevalence survey, HCV-RNA positivity declined from 22.1% in 2015 to 2.2% in 2019³³.

An important caveat before prescribing DAA is the exclusion of active HBV coinfection. Close monitoring of HBV reactivation is warranted, since hepatic HCV displacement using DAA might result in unwanted HBV surges^{34,35}.

Hepatitis D

The hepatitis D virus (HDV) is a unique small enveloped virus that requires HBV to complete its replication cycle, since HBsAg is part of the new released HDV particle. Hence, HDV is a defective agent. A recent meta-analysis pointed out that HDV is responsible for 18% of cirrhosis and 20% of HCC in individuals with chronic HBV infection globally. Thus, almost one-fifth of all HBV-related deaths in 2019 were attributable to HDV infection²³.

Eight HDV genotypes have been reported, each with a distinct geographic distribution and pathogenicity³⁶. Genotype 1 is prevalent worldwide. Genotype 2 is mostly reported in Russia, Taiwan and Japan. Genotype 3 is common in the Amazon Basin and is associated with more severe forms of liver disease, earlier onset of HCC and outbreaks of fatal acute liver failure. Genotype 4 is reported in the Far East, including Japan and Taiwan. Genotypes 5-8 are reported in Africa³⁷; and in Europe among African immigrants.

Sexual transmission and injection drug use are by far the most common routes of contagion for both HIV and HDV^{8,38}. However, in regions where any of these viruses are endemic and access to mother-to-child preventive measures are limited, perinatal transmission still occurs^{8,38}. The most common situation for HDV is vertically acquired hepatitis B and years later HDV superinfection during childhood or early sexually active adulthood³⁸.

The WHO has global estimates for hepatitis B and C²⁴, but it does not have figures of prevalence or mortality for HDV. Despite being a neglected disease, hepatitis delta is included as part of the Global Health Sector Strategy on Viral Hepatitis that in 2016 called for the elimination of all viral hepatitis by 2030, meaning at least 65% reduction in mortality and 90% decline in incidence²⁵. Approaches envisioned by the WHO to face the challenge of HDV control have recently been released³⁹. Expanding HBV vaccination and HDV testing are key elements of this roadmap. However, specific interventions in target populations as PLWH are scarcely addressed.

During the last couple of years, a vivid discussion in the scientific literature has been around the number of persons with hepatitis delta worldwide^{40,41}. The most recent global estimate is 0.7%, which translates in 13% of HBsAg+ patients⁴². Given that only a fraction (less than two thirds) of anti-HDV positive persons replicate the virus, the absolute number of HDV viremic individuals should be between 15 and 25 million people worldwide.

By order, Asia, Africa, South America, Middle East, Eastern Europe and Western Pacific islands are the regions with the largest HDV populations^{38,41} (Fig. 5). The five countries with the largest number of individuals with chronic hepatitis delta are China, Nigeria, Pakistan, Mongolia and Romania. Of note, there are no reliable data from Russia and China, where HDV rates are high and underestimated^{38,41,43}. Mongolia, a country geographically in between, has one of the greatest HDV rates worldwide (30% of HBsAg+). In the Western Pacific, high HDV rates have been reported in Micronesia, whereas Polynesia and Melanesia depict low HDV rates⁴⁴.

Temporal trends in HIV and HDV infections are divergent. The widespread use of antiretroviral therapy has reduced HIV transmission significantly in most regions. However, 1.5 million new HIV infections still occur annually worldwide⁸. The introduction of treatment as early as HIV diagnosis is made and the prescription of antiretrovirals as pre-exposure prophylaxis in

HIV-uninfected individuals engaged in high-risk behaviors has largely impacted among MSM^{9,45}. For other risk groups, such as PWID, both individual and social challenges frequently preclude them to take all advantages from medical services, including periodic testing, HBV vaccination and access to medications⁴⁶. All these unfavorable factors increase the likelihood of HDV acquisition^{47,48}.

In a recent survey conducted in Europe, 15% of nearly 2800 PLWH with HBsAg+ had HDV antibodies⁴⁹. However, whereas it was only 5% among MSM, resembling the rate seen in the general HIV-negative population with HBsAg+, it rose to 50% among PWID [49]. These numbers are similar to those reported in prior surveys conducted in PLWH in Europe more than one decade ago⁵⁰. Thus, PWID represents the largest HDV reservoir among PLWH in Europe and North America. In the rest of the world, the contribution of sexual risk groups to the HDV reservoir is greater⁵¹.

Producing estimates of the global population with HIV and HDV coinfection is difficult. Given that HDV only occurs among HBsAg+ individuals, if we assume that the rate of HBsAg among PLWH ranges from 5% to 10%, and there are 38 million PLWH worldwide, the population with HIV-HBV coinfection will range from 2 to 4 million. Then, if we apply the 15% rate of anti-HDV seen among European PLWH with HBsAg+^{49,50}, the estimated number of HIV-HDV coinfecting persons will range between 350,000 and 700,000 people worldwide.

Double and triple viral hepatitis infections may occur in PLWH, including HBV plus HCV, or HBV plus HDV plus HCV⁵². Classically, these patients exhibit the worst outcomes⁵³. Viral interference phenomena may occur with hepatic displacement of one virus when replication of another hepatitis virus takes over. In this situation, antiviral treatment of all replicating viruses should be encouraged⁵⁴.

Considering HIV and HDV overlapping geographic distribution, predominant transmission routes, HBsAg+ prevalence, and survival rates, it could be expected that roughly 0.5 million persons might be dually infected worldwide. Two major patterns of HIV and HDV coinfection that exhibit distinct HIV-1 variants and HDV genotypes can be recognized. In North America and Europe, HIV-1 subtype B and HDV genotype 1 are the predominant coinfections, being men more frequently affected than women. MSM and PWID are the largest groups^{47,51}. A second pattern of HIV-HDV coinfection occurs in Sub-Saharan Africa, where multiple HIV-1 non-B subtypes circulate and coinfection with HDV




Figure 5. *Hepatitis delta. Global geographic distribution and major endemic regions.*

genotypes 5-8 predominate along with HDV-1. Heterosexual transmission of HIV and HDV is the most common, being women more affected than men³⁸. As result of migrant flows, this second pattern of HIV-HDV coinfection is increasingly being recognized in Europe and North America^{55,56}.

In earlier studies, a severe course of liver disease was described in chronic hepatitis D patients, with faster pace toward liver cirrhosis with subsequent high liver-related morbidity and mortality^{57,58}. However, many of those studies included risk groups as PWID or patients with multiple comorbidities, including HIV or diabetes. During the last decade, the epidemiological landscape of hepatitis delta has changed with domestic cases decreasing while increasing the proportion of younger individuals immigrating from endemic regions to low-endemic regions^{55,56}. Recent insights into the spectrum of HDV disease have highlighted an indolent course in a substantial proportion of persons with hepatitis delta⁵⁹. However, at diagnosis, up to 30% might already show cirrhosis. Older age, liver cirrhosis, and HIV coinfection are the main predictors of worse clinical outcome for hepatitis delta^{56,60}.

In PLWH, chronic hepatitis delta has been associated with a disproportionate rate of cirrhosis and poor clinical outcomes. In a case-control study, 26 HIV/HDV-coinfected patients experienced significantly higher rates of hepatitis flares, liver cirrhosis, liver decompensation, and death over a median follow-up of 55 months

than matched HIV-monoinfected controls⁵³. More recently, two larger studies have examined the risk of liver decompensation and HCC in PLWH with hepatitis delta. In one Spanish study⁶¹, 1147 PLWH (mean age, 42 years; 81% males; 46% PWID, 85% on ART) were followed for a mean of 8 years. Overall, 15 patients died of liver-related complications and 26 developed hepatic decompensation events. The major predictors of hepatic outcomes were HDV coinfection and baseline liver fibrosis. Of note, three out of 17 PLWH with hepatitis delta developed HCC during the study period.

The second study reported data from the Swiss Cohort⁶². Overall, 15% of 818 HBsAg+ individuals had antibodies to HDV infection, of whom 63% had active HDV replication (detectable and measurable serum HDV-RNA). During a median follow-up of 8 years, PLWH with hepatitis delta were 8 times more likely to die from liver-related causes and 9 times more likely to develop HCC.

Hepatitis E

The hepatitis E virus (HEV) is a non-enveloped agent with a RNA genome. HEV is the most frequent cause of acute viral hepatitis worldwide⁶³. Each year produces over 3 million clinical cases, 70,000 deaths, and 3,000 stillbirths, mostly in Asia and Africa⁶³. HEV infection mostly affects persons living in resource-limited settings with poor access to clean water and sanitation. Acute hepatitis E can be particularly severe in

pregnant women and neonates⁶⁴. Indeed, HEV is a significant contributor to global maternal mortality, with reported case fatality rates of 20-30%.

Four HEV genotypes have been described. HEV genotypes 1 and 2 cause epidemics of acute hepatitis E and is largely transmitted by fecal contamination of water and food in highly endemic regions for HEV in Asia, Africa and Latin America. In contrast, HEV genotypes 3 and 4 cause sporadic acute hepatitis E cases in Europe and Asia, respectively, frequently following the consumption of non or poorly cooked meat⁶⁵. Hence, in this occasion, hepatitis E is a zoonosis. Precisely, it was in France where the first cases of chronic hepatitis E were described among transplant recipients⁶⁶. Since then, chronic hepatitis E has also been reported among other immunocompromised individuals, including PLWH^{67,68}.

Hepatitis E may affect other organs than the liver. Extrahepatic complications include Guillain-Barré syndrome, neuralgic amyotrophy, glomerulonephritis, cryoglobulinemia, pancreatitis, thrombopenia, meningitis, thyroiditis, and myocarditis⁶⁹. These manifestations have been associated to either a direct cytopathic tissue damage by HEV replication or to an overwhelming host immune response.

To date, there is a limited availability and usage of diagnostic tools for the serologic and/or molecular diagnosis of HEV, as well as a paucity of antiviral treatment options. Moreover, though an anti-HEV vaccine exists, it is only licensed in China and has not been authorized yet by the WHO for use in endemic settings and/or outbreaks. Ribavirin has been used as treatment of symptomatic or chronic hepatitis E, generally with poor results⁷⁰.

Both acute and chronic hepatitis E have both been described in PLWH, especially among MSM⁷¹⁻⁷³ and in the subset of patients with low CD4 counts, respectively⁷². However, to date, there is no evidence in favor of sexual HEV transmission^{74,75}.

Interventions to reduce the burden of viral hepatitis in PLWH

Although viral hepatitis will continue to challenge PLWH, the resumption of both preventive and curative strategies promises new hopes after the disruption caused by the COVID-19 pandemic. Renewed efforts should cover all steps of the medical care cascade, from expanding testing and vaccination of susceptible individuals to provision of medications as soon as possible to infected patients (Fig. 6).

Acute viral hepatitis A and E will continue to be a challenge in resource poor settings where these viruses are highly endemic. Although PLWH are not an increased risk for liver disease severity neither with HAV or HEV, protection by HAV vaccines may be lower in immunodeficient individuals and there is a risk for HEV chronification in the subset of PLWH with profound immunodeficiency.

Following the introduction of potent HBV and HCV antivirals, the clinical burden of chronic viral hepatitis has steadily declined globally^{23,28}. However, this slow-down seems to have reached a plateau, even after discounting the distraction caused by the COVID-19 pandemic. A similar phenomenon has been noticed with respect to new infections by human retroviruses⁷⁶.

There are three major reasons to explain this slow-down in incident cases, one for each of the chronic hepatitis viruses. First, HBV antivirals can control but not cure (eradicate) hepatitis B. The virus stays in the liver of HBsAg+ patients and favors the development of liver cancer even in the absence of cirrhosis. This finding has clearly been demonstrated in a large study performed in Spain examining nationwide hospitalizations over the past 20 years⁷⁷.

To push down further new incident hepatitis B, renewed efforts on HBV vaccination are warranted. Immunity waning in PLWH most likely account for unexpected low anti-HBs rates seen in recent studies⁷⁸.

Second, given that there is no protective immunity, HCV reinfections are frequent in persons that continue to be engaged in high-risk behaviors, including MSM with multiple sex partners or PWID sharing needles. In these groups, new exposures to HCV may blunt the benefit of any prior curative course of HCV therapy⁷⁹⁻⁸¹. The good news is that prescription for 3 months of oral DAA will cure hepatitis C in almost all patients any time, halting the development of both hepatic and extrahepatic complications⁸².

Third, the lack of effective therapy for hepatitis delta explains that chronic HDV infection is taking over hepatitis B or C as cause of morbidity and mortality in PLWH. Chronic HDV infection occurs in roughly 15% of PLWH and hepatitis B^{49,50}. As hepatitis delta is the most aggressive of all chronic viral hepatitis, most PLWH with hepatitis delta progress to liver cirrhosis and may develop liver cancer^{61,62}. No effective antiviral therapy had been developed until recently to treat hepatitis delta, but the advent of a subcutaneous entry inhibitor, bulevirtide, has opened a new era for hepatitis delta⁸³ (Table 2).




Figure 6. The cascade of care for viral hepatitis.

New strategies for viral hepatitis B and C

New approaches merit further consideration for viral hepatitis, based on the good results achieved confronting HIV infection. Among others, we will discuss the use of point-of-care (POC) tests, simpler treatment protocols, pre-exposure prophylaxis, and development of long-acting antivirals.

Rapid tests

Although 10 million hepatitis C patients had received DAA until 2020, only 20% of those infected worldwide had been diagnosed and 13% treated. To address this gap, POC viral load assays have recently been recommended by the WHO for hepatitis C⁸⁴. These tests for diagnosis and treatment monitoring have already shown their benefit on tuberculosis and HIV. The use of POC HCV viral load assays is especially relevant for promoting linkage to care for hard to reach or marginalized populations at high risk of loss to follow-up, and at decentralized HCV testing and treatment sites that might include opioid harm reduction services, primary clinics, prisons as well as STI and HIV clinics⁸⁴.

Simpler treatment protocols

The need to simplify HCV treatment approaches, particularly with the availability of low-cost generic drug formulations and to facilitate HCV elimination globally, has pushed studies that could minimize care requests using DAA. In this regard, the results from the

real-world ACTG trial MINMON (Minimal Monitoring) are very appealing⁸⁵. The study gave DAA therapy right on confirmation of HCV viremia, routine laboratory evaluations to assess cirrhosis (using the FIB-4 index), and exclusion of active HBV infection. A 12-week course of sofosbuvir/velpatasvir (84 tablets) with no in-person follow-up or laboratory evaluations was made until 12 weeks after completion of treatment. Pre-treatment HCV genotyping was not performed. Remote (telephone) contact was scheduled at weeks 4 and 22. The study enrolled 400 participants globally, of whom 42% were coinfecting with HIV. Sustained virologic response was attained by 95% (379/399) of participants, and no serious adverse events were noticed⁸⁵.

Pre-exposure prophylaxis

A protective effect of tenofovir on HBV acquisition comes from studies conducted in HIV patients on antiretroviral therapy⁸⁶. Sexually active men having sex with men (MSM) that received tenofovir as part of their antiretroviral regimen had a lower chance of HBV infection than those that did not receive the drug^{87,88}. Thereafter, this protective effect was also confirmed in HIV-uninfected persons at risk undergoing PrEP with tenofovir. Based on these findings, the recent increasing trend in HIV therapeutics for using dual regimens sparing tenofovir is worrisome⁸⁹. It might be associated with a rebound of incident HBV infections.

For all these considerations, the use of tenofovir as chemoprophylaxis might be discussed in certain populations to avert breakthrough HBV infections. We

Table 2. Current antivirals for chronic viral hepatitis

	Entry inhibitors	Nucleos(t)ide analogues	Protease inhibitors	NS5A inhibitors	Others*
HBV	Bulevirtide	Tenofovir Entecavir			Bepirovirsen
HCV		Sofosbuvir	Glecaprevir Voxilaprevir	Ledapasvir Velpatasvir Pibrentasvir	
HDV	Bulevirtide				Lonafarnib Interferon λ

*Expected approval soon

postulate that this could be the case for individuals engaged with high-risk behaviors, including PWID sharing needles and MSM with multiple sexual partners. Although HBV vaccines are effective, some individuals experience suboptimal responses and/or waning of antibodies following immunization⁹⁰. Moreover, circulation of HBV vaccine escape mutants is occasionally responsible for paradoxical acute HBV infections in vaccinated individuals⁹¹.

Long-acting antivirals

The advent of long-acting formulations of tenofovir could facilitate its prescription either as treatment or prevention^{92,93}. An additional indirect benefit of using tenofovir chemoprophylaxis would derive from reducing the chances of hepatitis delta acquisition, since this virus requires HBV for transmission⁹⁴.

In certain risk populations, such as PWID sharing needles and MSM with multiple sex partners, repeated episodes of HCV re-infection (occasionally more than 6)⁹⁵ have urged to reconsider the administration of repeated HCV courses. Given that the clinical consequences of chronic hepatitis C are generally seen only after decades of infection, some authors have advised against immediate anti-HCV treatment when high-risk behaviors persist. Against this view is the fact that being viremic means to be a potential source of contagion for others^{96,97}. In this scenario, the consideration of sofosbuvir as prevention of new HCV infections in persons engaged in risky behaviors and/or in prisons could be defended. This drug depicts high potency, good safety profile, limited number of drug interactions, and high barrier to resistance. After becoming HCV-RNA negative following a first course of therapy, sofosbuvir chemoprophylaxis could avert HCV

re-infections in high-risk individuals. Furthermore, if long-acting forms of HCV drugs become available⁹⁸, this option could be even more appealing.

Funding

None.

Conflicts of interest

None.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References

1. Del Olmo JA, Ornia E, Serra MA, Garcia-Torres ML, Escudero A, Rodríguez F, et al. Changing prevalence, clinical features, and outcome of acute hepatitis in Spain (1982-2003). *J Gastroenterol Hepatol.* 2006;21:982-7.
2. Barreiro P, Soriano V. Hepatitis A outbreaks in European homosexual men. *AIDS Rev.* 2017;19:113-4.
3. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the NEAT consensus conference. *AIDS.* 2011;25:399-409.
4. Soriano V, García-Samaniego J, Valencia E, Rodríguez-Rosado R, Muñoz F, González-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. *Eur J Epidemiol.* 1999;15:1-4.
5. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. *Am J Gastroenterol.* 2001;96:179-83.
6. Soriano V, Martín-Carbonero L, García-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with HIV. *Clin Infect Dis.* 2001;33:1793-5.

7. UNAIDS. HIV/AIDS Report. 2022. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_es.pdf
8. De Cok K, Jaffe H. Reflections on 40 years of AIDS. *Emerg Infect Dis*. 2021;27:1553-60.
9. Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. *JAMA*. 2023;329:63-84.
10. Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, et al. Liver cirrhosis in HIV-infected patients: prevalence, etiology and clinical outcome. *J Viral Hepat*. 2008;15:165-72.
11. Luetkemeyer AF, Wyles D. CROI 2021: viral hepatitis and other forms of liver injury impacting on people with HIV. *Top Antivir Med* 2021;29:379-85.
12. Kenfack-Momo R, Kenmoe S, Takuissu GR, Ebogo-Belobo JT, Kengne-Ndé C, Mbagwa DS, et al. Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with HIV in Africa: a systematic review and meta-analysis. *PLoS One*. 2022;17:e0269250.
13. Noël L, Tubiana R, Simon A, Valantin MA, Palich R, Blanc C, et al. Low immune response rate of HIV-infected patients to a single injection of hepatitis A vaccine. *Infect Dis Now*. 2021;51:94-6.
14. Zimmermann R, Faber M, Dudareva S, Ingiliz P, Jessen H, Koch J, et al. Hepatitis A outbreak among MSM in Berlin due to low vaccination coverage: epidemiology, management, and successful interventions. *Int J Infect Dis*. 2021;103:146-53.
15. McLaughlin SE, Simmons JD, Armstrong H, Gonzales E, Rakita RM, Duchin JS, et al. Acute hepatitis A viral infection in people with HIV with previously documented hepatitis A immunity or appropriate vaccination: a case series. *Open Forum Infect Dis*. 2021;8:ofab347.
16. Tsai PH, Tsai MS, Chiang YH, Shih CY, Liu CY, Chuang YC, et al. Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: is one dose enough? *J Microbiol Immunol Infect*. 2022;55:18-25.
17. Ishizaka A, Koga M, Mizutani T, Lim LA, Adachi E, Ikeuchi K, et al. Prolonged gut dysbiosis and fecal excretion of hepatitis A virus in patients infected with HIV. *Viruses*. 2021;13:2101.
18. Bazzardi R, Dore E, Ciccozzi M, Pisanu M, Babudieri S, Maida I. Outbreak of acute hepatitis A associated with MSM in North Sardinia 2017-2018. *J Infect Dev Ctries*. 2020;14:1065-70.
19. Bauer D, Farthofer A, Chromy D, Simbrunner B, Steininger L, Schmidbauer C, et al. Recent outbreaks of severe hepatitis A virus infections in Vienna. *Eur J Clin Microbiol Infect Dis*. 2021;40:335-44.
20. Oprea C, Popa I, Ianache I, Păun A, Vasile S, Târdei G, et al. Monkeypox, severe hepatitis A, and syphilis in an HIV returning traveler from Spain to Romania. *Travel Med Infect Dis*. 2022;50:102455.
21. Bogdanić N, Begovac J, Močibob L, Zekan S, Grgić I, Ujević J, et al. Hepatitis A outbreak in men who have sex with men using pre-exposure prophylaxis and people living with HIV in Croatia, January to October 2022. *Viruses*. 2022;15:87.
22. Dusheiko G, Agarwal K, Maini MK. New approaches to chronic hepatitis B. *N Engl J Med*. 2023;388:55-69.
23. GBD 2019 Hepatitis B Collaborators. Global, regional and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. *Lancet Gastroenterol Hepatol*. 2022;7:796-829.
24. World Health Organization. Global Hepatitis Report. Geneva: WHO; 2017.
25. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Geneva: WHO; 2016.
26. Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? *J Antimicrob Chemother*. 2008;62:1-4.
27. Spearman C, Dusheiko G, Hellard M, Sonderup M. Hepatitis C. *Lancet*. 2019;394:1451-66.
28. The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. *Lancet Gastroenterol Hepatol*. 2022;7:396-415.
29. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis*. 2016;16:797-808.
30. van Santen D, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, et al. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019. *EClinicalMedicine*. 2022;56:101810.
31. Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, et al. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection. *J Int AIDS Soc*. 2022;25:e26048.
32. Lens S, Miralpeix A, Gálvez M, Martró E, González N, Rodríguez-Tajes S, et al. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. *JHEP Rep*. 2022;4:100580.
33. Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, et al. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. *HIV Med*. 2022;23:705-16.
34. De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B coinfection as a further challenge. *J Clin Virol*. 2016;78:27-30.
35. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. *Clin Gastroenterol Hepatol*. 2017;15:132-6.
36. Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitis delta virus. *Emerg Infect Dis*. 2006;12:1447-50.
37. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al. Characterization of hepatitis delta virus in Sub-Saharan Africa. *J Clin Microbiol* 2014;52:1629-36.
38. Kushner T. Delta hepatitis epidemiology and the global burden of disease. *J Viral Hepat*. 2023 Jan 10. doi: 10.1111/jvh.13797. Epub ahead of print. PMID: 36625781.
39. Hayashi T, Takeshita Y, Hutin YJ, Harmanzi H, Easterbrook P, Hess S, et al. The global hepatitis delta virus epidemic: what gaps to address in order to mount a public health response. *Arch Public Health*. 2021;79:180.
40. Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. *Gut*. 2019;68:512-21.
41. Stockdale AJ, Kreuels B, Henrion MY, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. *J Hepatol*. 2020;73:523-32.
42. Miao Z, Pan Q. Revisiting the estimation of hepatitis D global prevalence. *J Hepatol*. 2020;73:1279-80.
43. Wedemeyer H, Negro F. Devil hepatitis D: an orphan disease or largely underdiagnosed? *Gut*. 2019;68:381-2.
44. Han M, Littlejohn M, Yuen L, Edwards R, Devi U, Bowden S, et al. Molecular epidemiology of hepatitis delta virus in the Western Pacific region. *J Clin Virol*. 2014;61:34-9.
45. Centers for Disease Control and Prevention. US Public Health Service: pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States-2021 Update: a Clinical Practice Guideline. Available from: www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf [Last accessed on 2023 Feb 2].
46. Soriano V, Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. *Nat Rev Gastroenterol Hepatol*. 2013;10:568-9.
47. Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. *AIDS*. 2017;31:875-84.
48. Ferrante ND, Lo Re V 3rd. Epidemiology, natural history and treatment of hepatitis delta virus infection in HIV/hepatitis B virus coinfection. *Curr HIV/AIDS Rep*. 2020;17:405-14.
49. Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter-Riniker F, Günthard HF, Rockstroh JK, Mocroft A, Rauch A, Peters L, Wandeler G; for EuroSIDA and SHCS. Hepatitis delta infection among persons living with HIV in Europe. *Liver Int*. 2023 Jan 10. doi: 10.1111/liv.15519. Epub ahead of print. PMID: 36625770.
50. Soriano V, Grint D, Monforte AD, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. *AIDS*. 2011;25:1987-92.
51. Chen S, Ren F, Huang X, Xu L, Gao Y, Zhang X, et al. Underestimated prevalence of HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) triple infection globally: systematic review and meta-analysis. *JMIR Public Health Surveill*. 2022;8:e37016.
52. Maida I, Rios MJ, Pérez-Saleme L, Ramos B, Soriano V, Pegram PS, et al. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. *AIDS Res Hum Retroviruses*. 2008;24:679-83.
53. Lee CY, Tsai HC, Lee SS, Wu KS, Sy CL, Chen JK, et al. Higher rate of hepatitis events in patients with HIV, hepatitis B, and hepatitis D genotype II infection: a cohort study in a medical center in southern Taiwan. *J Microbiol Immunol Infect*. 2015;48:20-7.
54. Soriano V, Barreiro P, Martín-Carbonero L, Castellares C, Ruiz-Sancho A, Labarga P, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. *J Infect Dis*. 2007;195:1181-3.
55. Aguilera A, Trastoy R, Barreiro P, Costa JJ, de Mendoza C, Peña JM, et al. Decline and changing profile of hepatitis delta among injection drug users in Spain. *Antivir Ther*. 2018;23:87-90.
56. Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV co-infection in the era of highly active antiretroviral therapy: a matched cohort study. *Clin Infect Dis*. 2007;44:988-95.
57. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. *Gastroenterology*. 2009;136:1629-38.
58. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. *Gut*. 2000;46:420-6.
59. Kamal H, Aleman S; D-SOLVE Consortium. Natural history of untreated HDV patients: Always a progressive disease? *Liver Int*. 2022 Oct 28. doi: 10.1111/liv.15467. Epub ahead of print. PMID: 36308026.

60. Ramos-Rincón JM, Pinargote H, Ramos-Belinchón C, de Mendoza C, Aguilera A, Soriano V. Hepatitis delta in patients hospitalized in Spain (1997-2018). *AIDS*. 2021;35:2311-8.
61. Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. *Clin Infect Dis*. 2014;58:1549-53.
62. Beguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, et al. Hepatitis delta-associated mortality in HIV/HBV coinfecting patients. *J Hepatol*. 2017;66:297-303.
63. Palewar MS, Joshi S, Choudhary G, Das R, Sadafale A, Karyakarte R. Prevalence of Hepatitis A virus (HAV) and Hepatitis E virus (HEV) in patients presenting with acute viral hepatitis: a 3-year retrospective study at a tertiary care Hospital in Western India. *J Family Med Prim Care*. 2022;11:2437-41.
64. Heemelaar S, Hangula AL, Chipeio ML, Josef M, Stekelenburg J, van den Akker TH, et al. Maternal and fetal outcomes of pregnancies complicated by acute hepatitis E and the impact of HIV status: a cross-sectional study in Namibia. *Liver Int*. 2022;42:50-8.
65. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. *Lancet*. 2012;379:2477-88.
66. Kamar N, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med*. 2008;358:811-7.
67. Buescher G, Ozga AK, Lorenz E, Pischke S, May J, Addo MM, et al. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. *Liver Int*. 2021;41:449-55.
68. Chaix ML, Leturque N, Gabassi A, Charreau I, Minier M, Pialoux G, et al. Prevalence and incidence of HEV among men using HIV pre-exposure prophylaxis: a sub-study of the ANRS IPERGAY trial. *J Clin Virol*. 2023;160:105380.
69. Wu J, Xiang Z, Zhu C, Yao Y, Bortolanza M, Cao H, et al. Extrahepatic manifestations related to hepatitis E virus infection and their triggering mechanisms. *J Infect*. 2021;83:298-305.
70. Neukam K, Barreiro P, Macías J, Avellón A, Cifuentes C, Martín-Carbonero L, et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. *Clin Infect Dis*. 2013;57:465-8.
71. Filipe R, Prista-Leão B, Silva-Pinto A, Abreu I, Serrão R, Costa R, et al. Hepatitis E in a Portuguese cohort of HIV-positive patients: high seroprevalence but no chronic infections. *Health Sci Rep*. 2022;5:e624.
72. Sherman KE, Kottlil S, Rouser SD, Abdel-Hameed EA, Boyce CL, Meeds HL, et al. Hepatitis E infection in a longitudinal cohort of hepatitis C virus and HCV/HIV-coinfecting persons. *AIDS Res Hum Retroviruses*. 2021;37:534-41.
73. Rivero-Juarez A, Frias M, Lopez-Lopez P, Berenguer J, García F, Macías J, et al. Hepatitis E 3ra genotype infection in people living with HIV in Spain. *Front Microbiol*. 2020;11:564486.
74. Madejón A, Vispo E, Bottecchia M, Sánchez-Carrillo M, García-Samaniego J, Soriano V. Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. *J Viral Hepat*. 2009;16:895-6.
75. Miguères M, Ducours M, Dimeglio C, Trimoulet P, Abravanel F, Delobel P, et al. No evidence of sexual transmission of HEV among individuals using HIV pre-exposure prophylaxis. *J Viral Hepat*. 2020;27:1495-501.
76. Soriano V, Carrizo P, Sauleda S, Richart A, Rando A, Miró E, et al. The slowdown of new infections by human retroviruses has reached a plateau in Spain. *J Med Virol*. In press.
77. Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, et al. Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain. *Aliment Pharmacol Ther*. 2023;57:540-8.
78. Soriano V, Aguilera A, Benito R, González-Díez R, Miró E, Liendo P, et al. Susceptibility to hepatitis B virus infection in adults living in Spain. *Liver Int*. 2023; In press.
79. Huang MH, Chen GJ, Sun HY, Chen YT, Su LH, Ho SY, et al. Risky sexual practices and hepatitis C viremia among HIV-positive men who have sex with men in Taiwan. *J Microbiol Immunol Infect*. 2023;In press.
80. Nishikawa K, Kimura M, Imamura J, Kimura K. Prevalence of hepatitis C virus infection among men who have sex with men with HIV-1 infection between 2010 and 2020 in Japan: a single-center retrospective cohort study. *J Infect Chemother*. 2023;29:263-8.
81. Wan Z, Sun P, Dzakah E, Huang L, Shuai P, Liu Y. Reinfection rate of hepatitis C in HIV-1 positive men who have sex with men: a systematic review and meta-analysis. *Front Public Health*. 2022;10:855989.
82. Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of direct-acting antiviral therapy with liver and non-liver complications and long-term mortality in patients with chronic hepatitis C. *JAMA Intern Med*. 2023;183:97-105.
83. Soriano V, Moreno-Torres V, Treviño A, Corral O, de Mendoza C. Bulevirtide in the treatment of hepatitis delta: drug discovery, clinical development and place in therapy. *Drug Des Devel Ther*. 2023;17:155-66.
84. Trickey A, Fajardo E, Alemu D, Artenie A, Easterbrook P. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2023;8:253-70.
85. Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. *Lancet Gastroenterol Hepatol*. 2022;7:307-17.
86. Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. *Clin Infect Dis*. 2013;56:1812-9.
87. Heuft MM, Houba SM, van den Berk G, van de Haere TS, van Dam AP, Dijkstra LM, et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. *AIDS*. 2014;28:999-1005.
88. Shilahi M, Marzel A, Scherrer AU, Braun DL, Kovari H, Rougemont M, et al. Dually active HIV/HBV antiretrovirals as protection against incident hepatitis B infections: potential for prophylaxis. *J Infect Dis*. 2016;214:599-606.
89. Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas D, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. *Lancet HIV*. 2020;7:e443-8.
90. Kim Y, Loucks J, Shah M. Efficacy of Hepatitis B Vaccine in Adults with Chronic Liver Disease. *J Pharm Pract*. 2022 Feb 24;8971900221078742. doi: 10.1177/08971900221078742. Epub ahead of print. PMID: 35202562.
91. Besombes J, Souala F, Bouguen G, Guyader D, Grohler C, Thibault V, et al. Acute hepatitis B virus infection despite vaccination in a patient treated by infliximab: a case report. *BMC Gastroenterol*. 2022;22:322.
92. Das S, Wang W, Ganesan M, Fonseca-Lanza F, Cobb DA, Bybee G, et al. A novel ultra-long acting tenofovir ProTide nanoformulation achieves months long HBV suppression. *Sci Adv*. 2022;8:eade9582.
93. Thomas DL, Kiser JJ, Baum MM. Long-acting treatments for hepatitis B. *Clin Infect Dis*. 2022;75(suppl 4):S17-24.
94. Soriano V, Alvarez C, Edagwa B, de Mendoza C, Montoya N, Treviño A, et al. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. *Int J Infect Dis*. 2022;114:45-50.
95. Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. *J Hepatol*. 2017;66:282-7.
96. Fernández-Montero JV, Aspinall E, Burns J. Treatment as prevention: should hepatitis C learn the lessons from HIV? *AIDS Rev*. 2017;19:212-8.
97. Spaulding AC, Anderson EJ, Khan MA, Taborda-Vidarte CA, Phillips JA. HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community's infections. *AIDS Rev*. 2017;19:134-47.
98. Verma M, Chu JN, Salama JA, Faiz MT, Eweje F, Gwynne D, et al. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. *Proc Natl Acad Sci USA*. 2020;117:11987-94.